|4. Switch to a TNFi biologic over abatacept (PICO 67)|Low (62–66, 72–78, 103, 104)|
|Conditional recommendation based on low-quality evidence; may consider abatacept if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease.| |
|5. Switch to a TNFi biologic over tofacitinib (PICO 76)|Low (62–66, 72–78, 105)|
|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers oral medication.| |
|6. Switch to an IL-17i over a different OSM (PICO 25)|Low (79–87, 89–95)|